Chimeric Anti-GPC3 sFv-CD3ε Receptor Modified T Cells with IL7 Co-Expression for the Treatment of Solid Tumors

To improve the efficacy and safety of glypican-3 (GPC3)-targeted adoptive cell therapies, T cells were modified with anti-GPC3 single-chain fragment variable (sFv) linked to CD3ε, which could be incorporated into the entire TCR/CD3 complex to form chimeric sFv-CD3ε receptor (sFv-ε).